Treatment response also increased with increased body mass index, with patients who had a BMI above 40 kg/m2 seeing testosterone levels improve by 2.64 nmol/L.
Along with higher testosterone, patients in the test group experienced improved grip strength and blood pressure.
Investigators chose targeting IL-1 receptor antagonist specifically because of previous successes with other conditions.
“We chose IL-1 because it has shown previous, very beneficial effects on glucose metabolism, with reductions of A1c, and is well tolerated,” Dr. Ebrahimi said in response to a question from the audience.
Dr. Ebrahimi and fellow investigators believe this study will help open the door on unanswered questions related to the cardiovascular safety of this kind of treatment.